Cell Proliferation News and Research

RSS

Src can be most promising targets for cancer therapy

Src (short for sarcoma) is a family of proto-oncogenic tyrosine kinases active in many cancer tumors, including medulloblastoma, the most common malignant cancer in children. Src represents one of the most promising targets for cancer therapy.

6 Apr 2010

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company's cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria, April 14-18, 2010.

6 Apr 2010

Treatment with beta-blockers can help reduce spread of cancer in patients with breast tumours

Treatment with beta-blockers can help reduce the spread of cancer in patients with breast tumours, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today (Friday).

26 Mar 2010

NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy

Two key, independent proof-of-concept studies conducted for NellOne Therapeutics, Inc. demonstrate the potential efficacy of the company’s lead therapeutic candidate for both skeletal muscle wound healing and myocardial infarction.

26 Mar 2010

New experiments may hold clues for controlling cancer

A protein discovered in fruit fly eyes has brought a Johns Hopkins team closer to understanding how the human heart and other organs automatically "right size" themselves, a piece of information that may hold clues to controlling cancer.

26 Mar 2010

How does a heart know when it's big enough?

25 Mar 2010

Study on zebrafish regenerate tissues links human heart implications

In a paper published in the March 25, 2010 issue of Nature, researchers working at the Salk Institute for Biological Studies and the Center of Regenerative Medicine in Barcelona (CMRB) identified a fish heart cell population that is the source of this astonishing healing feat, a finding that could provide insight into how mammalian hearts might be coaxed into repairing themselves after injury brought on by heart attack.

25 Mar 2010

Asuragen appoints BMD as exclusive distributor of Signature Oncology Products in France

Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA, a leading medical diagnostic company in Europe, as its exclusive distributor of Signature® Oncology Products in France. Asuragen’s Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies.

22 Mar 2010

Mayo Clinic co-led research finds first gene linked to lung cancer in "never smokers"

A five-center collaborative study that scanned the genomes of thousands of "never smokers" diagnosed with lung cancer as well as healthy never smokers has found a gene they say could be responsible for a significant number of those cancers.

22 Mar 2010

Research shows Caspase-1 protein plays a key role in the process of inflammation and colon cancer

Every day, our gut comes in contact with bacteria, inducing an inflammatory response that is tolerated and controlled. Sometimes the control of inflammation is lost and this can lead to inflammatory bowel disease that may predispose to colon cancer.

18 Mar 2010

Novel findings point to new therapeutic approaches for common types of cancer

Increased understanding of the Skp2 gene and its relation to cellular senescence may lead to the development of novel agents that can suppress tumor development in common types of cancer, researchers from The University of Texas M. D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature.

18 Mar 2010

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.

17 Mar 2010

Essen Instruments, Origene Technologies partner to co-develop ion channel cell lines

Essen Instruments Inc. and OriGene Technologies, Inc. today announced a strategic alliance to co-develop ion channel cell lines. Essen, based in Ann Arbor Michigan, is a leading provider of life science products and services, including ion channel discovery and safety assays. OriGene, headquartered in Rockville, Maryland, specializes in the creation and supply of gene-centric products, and has a collection of over 30,000 human full length cDNA clones.

17 Mar 2010

Key cellular defect in protein synthesis can lead to cancer susceptibility

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.

17 Mar 2010

Drug-eluting stents offer new hope to patients with critical limb ischemia

In the United States, more than 100,000 amputations are performed each year on individuals with critical limb ischemia, the most severe form of peripheral arterial disease (PAD). The number one priority in treating these patients is to re-establish blood flow to avoid limb amputation.

16 Mar 2010

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die. When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more.

15 Mar 2010

Chelsea Therapeutics announces financial results for fourth quarter 2009

Chelsea Therapeutics International, Ltd. reported financial results for the fourth quarter and full year 2009 and will host a conference call this afternoon at 4:30 PM ET to discuss these results and provide a quarterly update on the Company's development progress.

11 Mar 2010

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Rexahn Pharmaceuticals, Inc, a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®.

8 Mar 2010

mtm laboratories launches CINtec PLUS screening system for cervical cancer

mtm laboratories, a privately held diagnostics company today announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer. CINtec® PLUS will be launched with claims direct in Germany, Italy, Spain, France and the UK, and will also be available in other parts of the world via mtm’s nominated distributors.

8 Mar 2010

OSCC cells express VEGFR1, VEGFR2 and serve as targets and effectors for VEGF: Study

Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher M. Tong, The Ohio State University, will present a poster of a study titled "Epithelial-to-Endothelial Transition: An Epithelial Phenotypic Modulation Facilitating Oral-Squamous-Cell Carcinoma Progression."

5 Mar 2010

Cell Proliferation News and Research

Src can be most promising targets for cancer therapy

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

Treatment with beta-blockers can help reduce spread of cancer in patients with breast tumours

NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy

New experiments may hold clues for controlling cancer

How does a heart know when it's big enough?

Study on zebrafish regenerate tissues links human heart implications

Asuragen appoints BMD as exclusive distributor of Signature Oncology Products in France

Mayo Clinic co-led research finds first gene linked to lung cancer in "never smokers"

Research shows Caspase-1 protein plays a key role in the process of inflammation and colon cancer

Novel findings point to new therapeutic approaches for common types of cancer

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

Essen Instruments, Origene Technologies partner to co-develop ion channel cell lines

Key cellular defect in protein synthesis can lead to cancer susceptibility

Drug-eluting stents offer new hope to patients with critical limb ischemia

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Chelsea Therapeutics announces financial results for fourth quarter 2009

Rexahn Pharmaceuticals granted Japanese patent for Archexin

mtm laboratories launches CINtec PLUS screening system for cervical cancer

OSCC cells express VEGFR1, VEGFR2 and serve as targets and effectors for VEGF: Study

Event Guide: 3rd Annual TRP Supply Chain & Manufacturing Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News